Targeted DNA/RNA Sequencing Market to Reach USD 70.79 Billion by 2034, Growing at 19.40% CAGR: Polaris Market Research

According to a new report by Polaris Market Research, the global targeted DNA/RNA sequencing market was valued at USD 14.33 billion in 2025 and is projected to reach USD 70.79 billion by 2034, expanding at a CAGR of 19.40% over the forecast period. Growth is underpinned by rising adoption of next-generation sequencing (NGS) platforms, expanding precision medicine initiatives, and accelerating oncology and rare-disease research across key end-use industries.

What Is Driving Targeted DNA/RNA Sequencing Market Growth?

Demand is climbing as advancements in sequencing technology converge with the rising prevalence of genetic disorders. Manufacturers and end users are prioritizing precision medicine, pushing targeted DNA/RNA sequencing adoption across healthcare and biotechnology. Polaris analysts note that the sequencing cost of a whole human genome has dropped to roughly USD 600 from about USD 10,000 a decade ago, positioning the segment for sustained double-digit growth through 2034, with academic research emerging as the largest revenue contributor and pharma & biotech entities posting the fastest incremental gains.

Key Trends Shaping the Targeted DNA/RNA Sequencing Industry

AI-Enabled Variant Calling and Bioinformatics Automation

Artificial intelligence is improving variant detection accuracy, automating bioinformatics analysis, and reducing sequencing turnaround time, weaving advanced technology advancement into everyday clinical and research workflows.

Multiomics Integration and Precision Oncology

The integration of targeted DNA/RNA sequencing data with proteomic and metabolomic profiles is emerging as a significant trend, supporting the broader shift toward precision medicine and more accurate, holistic diagnostics.

Falling Sequencing Costs and New Platform Launches

Sharp declines in NGS pricing and new high-throughput platform launches are reshaping the competitive landscape and market outlook. In June 2026, Roche launched AXELIOS 1, an NGS platform powered by SBX technology capable of end-to-end, same-day whole-genome sequencing.

👉 Explore The Complete Comprehensive Report Here:

https://www.polarismarketresearch.com/industry-analysis/targeted-dna-rna-sequencing-market

Market Segmentation: Breaking Down the Targeted DNA/RNA Sequencing Market

Polaris segments the targeted DNA/RNA sequencing market by type, method, workflow, end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Type

The DNA-based segment led the market in 2025, accounting for 62.7% of revenue, on the strength of its broad application across cancer research, genetic disorder analysis, and pharmacogenomics. The RNA-based segment is projected to expand at a faster pace through 2034 as growing interest in gene expression and transcriptomics, alongside falling sequencing costs, widens its research and clinical use.

By Method

Exome sequencing remains the dominant method, driven by its established role in identifying disease-related genetic alterations. Enrichment sequencing is gaining share as the fastest-growing method, signaling where near-term demand and search intent around "targeted panel sequencing" is shifting as precision medicine adoption expands.

By Workflow

Among workflow stages, sequencing captured the largest share at 56.9% of revenue in 2025, while data analysis is expected to post the strongest incremental growth, reflecting rising demand for advanced bioinformatics tools as genomic data volumes expand.

By End User

Among end users, academic research captured the largest share in 2025, supported by continuous funding and grant-backed genomic studies, while pharma & biotech entities are expected to post the strongest incremental growth as drug developers integrate genomic insights into clinical trials and personalized therapeutics.

Regional Outlook: Where Is Targeted DNA/RNA Sequencing Growing Fastest?

North America led the market in 2025 with a 42.1% share, on the back of advanced healthcare infrastructure, high research funding, and early adoption of precision medicine, while Asia Pacific is expected to post the fastest CAGR of 13.4% through 2034, driven by rising healthcare infrastructure and biotechnology investment. Within North America, the United States remains the largest single market; within Asia Pacific, China and India are the primary growth engines. Europe rounds out the top three, supported by the EU's Horizon Europe program and strong biotech activity in Germany, the UK, and France.

👉 Explore the Full Targeted DNA/RNA Sequencing Market Report:

https://www.polarismarketresearch.com/industry-analysis/targeted-dna-rna-sequencing-market

Competitive Landscape: Leading Targeted DNA/RNA Sequencing Companies

Key players profiled in the report include Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, Roche Sequencing Solutions, and QIAGEN, who are focusing on product launches, capacity expansion, and strategic partnerships to strengthen market position across the DNA-based and exome sequencing segments outlined above. Recent moves include Roche's June 2026 launch of the AXELIOS 1 NGS platform, powered by SBX technology for same-day whole-genome sequencing, and its February 2025 introduction of the SBX sequencing platform, both aimed at deepening share in North America and Europe. Other significant participants include Pacific Biosciences, Oxford Nanopore Technologies, BGI Genomics, Genomatix Software, Bio-Rad Laboratories, PerkinElmer, HudsonAlpha, Element Biosciences, Twist Bioscience, and Nextera.

Why It Matters for Buyers Evaluating the Targeted DNA/RNA Sequencing Market

For stakeholders researching targeted DNA/RNA sequencing market forecasts, this report benchmarks market share, segment-level pricing, and forecast data by type, method, workflow, end user, and region to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking data analysis and multiomics integration as growth adjacencies.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Glycerol Derivatives Market

Europe Commercial Vehicles Market

Self-Healing Construction Materials Market

T4 DNA Ligase Market

Europe Commercial Vehicles Market

Substation Automation Market

Aroma Chemicals Market

Glass Mat Market: A Necessary Construction Component for Modern Building Technologies

Voluntary Carbon Credit Market